Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Perspectum Diagnostics – a spinout from the Radcliffe Department of Medicine – has reinvested money in the University of Oxford, to fund a three year multicentre European health economic study into methods of diagnosing fatty liver disease. This first of three payments totaling €759,999, is part of a €3.4m project, won by Perspectum in the H2020 grant competition.

© Perspectum Diagnostics
Liver scan. Image credit, Perspectum Diagnostics

Perspectum Diagnostics has developed an MRI scanning technique to detect and monitor non-alcoholic fatty liver disease (NAFLD) – a rising concern due to its links with obesity and diabetes. LiverMultiScan offers a safe and non-invasive method to aid diagnosis of liver disorders. Patients are already benefitting from the technology, which was introduced in Europe and the U.S. as a research device in 2014. It has now been made available in leading medical institutions in 50 hospitals, globally.

Read more (Radcliffe Department of Medicine website)

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.